DeuterOncology
clinical-stage drug development company
DeuterOncology has raised €5.7M across 1 funding round from 3 investors, most recently a Series A round in Jan 2023. Based in Liege, Belgium; active in Healthtech. Data as of 4 Nov 2026.
Total raised
€5.7M
€5,650,000
Funding rounds
1
Investors
3
distinct backers
Active since
2023-01
latest 2023-01
Funding by year
EUR raised per yearDeuterOncology — funding by year — interactive chart.
Data table
| DeuterOncology — funding by year | |
|---|---|
| 2023 | €5.7M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-01-19 | Series A | €5.7M | Investsud Tech,Newton Biocapital,Noshaq | View deal → |
Investors
3Related news
- DeuterOncology Closes €5.65M Series A Financing Roundfinsmes.com · 2023-01
Similar companies
same sector, similar size- Awell Health€6.7MBelgium · Healthtech
- Byteflies€4.5MBelgium · Healthtech
- Hippo Dx€4.4MBelgium · Healthtech
- Pulsify Medical€5.4MBelgium · Healthtech
- Nuclivision€5.0MBelgium · Healthtech
- Mindoo€5.0MBelgium · Healthtech
Global coverage: FundingData